Abstract
Atopic dermatitis (AD) is a chronic inflammatory skin disease which affects some 10 - 15% of the population during childhood. The prevalence of the disease is increasing and there are few, if any, current therapies which are directed at the underlying cause of the disease. A better understanding of the mechanisms of AD is starting to offer potential therapeutic approaches to this disease. The understanding of the role of cytokines in AD, in particular interleukin-4, interferon-gamma and tumour necrosis factor-alpha, has indicated several potential approaches, including inhibition of cytokine processing (matrix metalloproteinase inhibitors), inhibition of cytokine release (phosphodiesterase type IV inhibitors) and modulation of cytokine levels, as well as newer approaches to immunomodulation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
